Merck races ahead of Bristol-Myers in lung cancer drug therapy
Category: #health  By Dhananjay Punekar  Date: 2018-04-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck races ahead of Bristol-Myers in lung cancer drug therapy

Pharma major Merck has apparently emerged at the top, surpassing Bristol-Myers Squibb, in the results of the clinical trials that demonstrated the effectiveness of immunotherapy medicines. As per sources, Merck’s Keytruda and Bristol’s Opdivo have proved to be more successful in treating lung cancer as compared to chemotherapy.

Reportedly, the outcomes of the trials displayed that when lung cancer patients in the U.S. were treated with Merck’s drug Keytruda along with chemotherapy, their rate of survival increased by 51% as compared to those subjects treated with only chemotherapy. However, the subjects treated with Bristol-Myers Squibb’s medicine Opdivo along with another medicine Yervoy was found to reduce death risks by 42% as compared to the patients treated only with chemo.

Sources cite that these clinical tests focused on two measures of survival. The first measure was focused on how long subjects can survive after treating them with the drugs along with chemo. Another measure was the progression-free survival rate – meaning, determining how much longer the lung cancer patients survive without the growth of cancerous tumors.

Apparently, during the trials conducted in the U.S., patients treated with chemotherapy only survived for a 11.3 months median span. However, the subjects treated with both Merck’s Keytruda and chemo had a longer survival rate. In case of Bristol’s Opdivo, the outcomes focused more on progression-free survival among the lung cancer patients for nearly 11.5 months.

For the record, lung cancer is one of the major causes of cancer-related deaths across the U.S. Over 2,34,000 citizens in the country are predicted to be diagnosed for lung cancer this year and over 1,54,000 lung cancer patients are likely to die due to the disease.

Healthcare professionals state that the effectiveness of the medicines is also measured on parameters such as safety and costs. A reputed medical expert has claimed that Bristol’s Opdivo & Yervoy drug combination exhibited lower safety rate as compared to chemotherapy. Incidentally, Merck’s Keytruda also demonstrated side-effects such as nausea, fatigue, anemia, and acute kidney damage in the lung cancer patients.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...